WELL Health's Wisp Surpasses One Million Patients Served and $100M CAD in Runrate Revenues and Rolls out Ambitious Growth Plan

In This Article:

  • Wisp surpasses one million patients, solidifying its status as the largest and fastest-growing telehealth platform in the United States serving women's health needs with a focus on sexual and reproductive health.

  • July 2024 revenue run rate exceeds USD$78 million, bringing Wisp's annualized revenue to over CAD$100 million. Wisp achieved 30% year-over-year revenue growth with less than $2 million in primary capital, highlighting its efficient and scalable growth model.

  • Wisp continues to innovate with the launch of over ten new products, including expanded offerings in fertility, menopause, and at-home testing while it prepares for additional significant product launches later this year.

NEW YORK and VANCOUVER, BC, Aug. 21, 2024 /CNW/ - WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF) ("WELL" or the "Company"), a digital healthcare company focused on positively impacting health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, is pleased to announce that its majority-owned subsidiary, Wisp, the leading sexual and reproductive telehealth provider in the United States, has officially achieved two important milestones. It has surpassed: 1- one million patients served nationwide in the United States and 2- Recorded more than $78M US or $100M CAD in runrate revenue for the first time based on its July results. This milestone firmly establishes Wisp as the largest and fastest-growing telehealth platform for women, offering innovative and first-to-market products throughout every stage of a woman's health journey.

WELL Health Technologies (CNW Group/WELL Health Technologies Corp.)

"Reaching well over one million patients and continuing our revenue runrate to over $78M US with profitability is a profound testament to Wisp's mission to redefine women's health with a focus on sexual and reproductive healthcare," said Monica Cepak, CEO of Wisp. "With 10% of our patient base residing in areas of the US where there are significant impediments to access care, we are dedicated to expanding access to essential healthcare services. As we look ahead, we are eager to not only enhance our offerings in diagnostics, fertility, and menopause care, but we are also gearing up for some of our most ambitious product launches to date, expected later this year."

In July 2024, Wisp surpassed USD$6.5 in revenues marking a significant milestone in its rapid ascent as a leader in women's telehealth. This growth is fueled by increasing demand for Wisp's innovative healthcare solutions, reflected in a 30% year-over-year revenue increase and the ability to consistently generate positive EBITDA with minimal capital investment.